Cargando…

Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival

Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologicall...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Azadeh, Korshunov, Andrey, Reifenberger, Guido, Capper, David, Felsberg, Joerg, Trisolini, Elena, Pollo, Bianca, Calatozzolo, Chiara, Prinz, Marco, Staszewski, Ori, Schweizer, Leonille, Schittenhelm, Jens, Harter, Patrick N., Paulus, Werner, Thomas, Christian, Kohlhof-Meinecke, Patricia, Seiz-Rosenhagen, Marcel, Milde, Till, Casalini, Belén M., Suwala, Abigail, Wefers, Annika K., Reinhardt, Annekathrin, Sievers, Philipp, Kramm, Christof M., Etminam, Nima, Unterberg, Andreas, Wick, Wolfgang, Herold-Mende, Christel, Sturm, Dominik, Pfister, Stefan M., Sill, Martin, Jones, David T. W., Schrimpf, Daniel, Reuss, David E., Aldape, Ken, Abdullaev, Zied, Sahm, Felix, von Deimling, Andreas, Stichel, Damian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751269/
https://www.ncbi.nlm.nih.gov/pubmed/35012690
http://dx.doi.org/10.1186/s40478-021-01308-1
_version_ 1784631647624232960
author Ebrahimi, Azadeh
Korshunov, Andrey
Reifenberger, Guido
Capper, David
Felsberg, Joerg
Trisolini, Elena
Pollo, Bianca
Calatozzolo, Chiara
Prinz, Marco
Staszewski, Ori
Schweizer, Leonille
Schittenhelm, Jens
Harter, Patrick N.
Paulus, Werner
Thomas, Christian
Kohlhof-Meinecke, Patricia
Seiz-Rosenhagen, Marcel
Milde, Till
Casalini, Belén M.
Suwala, Abigail
Wefers, Annika K.
Reinhardt, Annekathrin
Sievers, Philipp
Kramm, Christof M.
Etminam, Nima
Unterberg, Andreas
Wick, Wolfgang
Herold-Mende, Christel
Sturm, Dominik
Pfister, Stefan M.
Sill, Martin
Jones, David T. W.
Schrimpf, Daniel
Reuss, David E.
Aldape, Ken
Abdullaev, Zied
Sahm, Felix
von Deimling, Andreas
Stichel, Damian
author_facet Ebrahimi, Azadeh
Korshunov, Andrey
Reifenberger, Guido
Capper, David
Felsberg, Joerg
Trisolini, Elena
Pollo, Bianca
Calatozzolo, Chiara
Prinz, Marco
Staszewski, Ori
Schweizer, Leonille
Schittenhelm, Jens
Harter, Patrick N.
Paulus, Werner
Thomas, Christian
Kohlhof-Meinecke, Patricia
Seiz-Rosenhagen, Marcel
Milde, Till
Casalini, Belén M.
Suwala, Abigail
Wefers, Annika K.
Reinhardt, Annekathrin
Sievers, Philipp
Kramm, Christof M.
Etminam, Nima
Unterberg, Andreas
Wick, Wolfgang
Herold-Mende, Christel
Sturm, Dominik
Pfister, Stefan M.
Sill, Martin
Jones, David T. W.
Schrimpf, Daniel
Reuss, David E.
Aldape, Ken
Abdullaev, Zied
Sahm, Felix
von Deimling, Andreas
Stichel, Damian
author_sort Ebrahimi, Azadeh
collection PubMed
description Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01308-1.
format Online
Article
Text
id pubmed-8751269
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87512692022-01-11 Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival Ebrahimi, Azadeh Korshunov, Andrey Reifenberger, Guido Capper, David Felsberg, Joerg Trisolini, Elena Pollo, Bianca Calatozzolo, Chiara Prinz, Marco Staszewski, Ori Schweizer, Leonille Schittenhelm, Jens Harter, Patrick N. Paulus, Werner Thomas, Christian Kohlhof-Meinecke, Patricia Seiz-Rosenhagen, Marcel Milde, Till Casalini, Belén M. Suwala, Abigail Wefers, Annika K. Reinhardt, Annekathrin Sievers, Philipp Kramm, Christof M. Etminam, Nima Unterberg, Andreas Wick, Wolfgang Herold-Mende, Christel Sturm, Dominik Pfister, Stefan M. Sill, Martin Jones, David T. W. Schrimpf, Daniel Reuss, David E. Aldape, Ken Abdullaev, Zied Sahm, Felix von Deimling, Andreas Stichel, Damian Acta Neuropathol Commun Research Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA encompassed 144 tumors all subjected to DNA methylation array analysis. Sixty-two histPXA matched to the methylation class mcPXA. These were combined with the cases that showed the mcPXA signature but had received a histopathological diagnosis other than PXA. This cohort constituted a set of 220 mcPXA. Molecular and clinical parameters were analyzed in these groups. Morphological parameters were analyzed in a subset of tumors with FFPE tissue available. HistPXA revealed considerable heterogeneity in regard to methylation classes, with methylation classes glioblastoma and ganglioglioma being the most frequent mismatches. Similarly, the mcPXA cohort contained tumors of diverse histological diagnoses, with glioblastoma constituting the most frequent mismatch. Subsequent analyses demonstrated the presence of canonical pTERT mutations to be associated with unfavorable prognosis among mcPXA. Based on these data, we consider the tumor type PXA to be histologically more varied than previously assumed. Histological approach to diagnosis will predominantly identify cases with the established archetypical morphology. DNA methylation analysis includes additional tumors in the tumor class PXA that share similar DNA methylation profile but lack the typical morphology of a PXA. DNA methylation analysis also assist in separating other tumor types with morphologic overlap to PXA. Our data suggest the presence of canonical pTERT mutations as a robust indicator for poor prognosis in methylation class PXA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01308-1. BioMed Central 2022-01-10 /pmc/articles/PMC8751269/ /pubmed/35012690 http://dx.doi.org/10.1186/s40478-021-01308-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ebrahimi, Azadeh
Korshunov, Andrey
Reifenberger, Guido
Capper, David
Felsberg, Joerg
Trisolini, Elena
Pollo, Bianca
Calatozzolo, Chiara
Prinz, Marco
Staszewski, Ori
Schweizer, Leonille
Schittenhelm, Jens
Harter, Patrick N.
Paulus, Werner
Thomas, Christian
Kohlhof-Meinecke, Patricia
Seiz-Rosenhagen, Marcel
Milde, Till
Casalini, Belén M.
Suwala, Abigail
Wefers, Annika K.
Reinhardt, Annekathrin
Sievers, Philipp
Kramm, Christof M.
Etminam, Nima
Unterberg, Andreas
Wick, Wolfgang
Herold-Mende, Christel
Sturm, Dominik
Pfister, Stefan M.
Sill, Martin
Jones, David T. W.
Schrimpf, Daniel
Reuss, David E.
Aldape, Ken
Abdullaev, Zied
Sahm, Felix
von Deimling, Andreas
Stichel, Damian
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title_full Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title_fullStr Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title_full_unstemmed Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title_short Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival
title_sort pleomorphic xanthoastrocytoma is a heterogeneous entity with ptert mutations prognosticating shorter survival
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751269/
https://www.ncbi.nlm.nih.gov/pubmed/35012690
http://dx.doi.org/10.1186/s40478-021-01308-1
work_keys_str_mv AT ebrahimiazadeh pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT korshunovandrey pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT reifenbergerguido pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT capperdavid pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT felsbergjoerg pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT trisolinielena pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT pollobianca pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT calatozzolochiara pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT prinzmarco pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT staszewskiori pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT schweizerleonille pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT schittenhelmjens pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT harterpatrickn pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT pauluswerner pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT thomaschristian pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT kohlhofmeineckepatricia pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT seizrosenhagenmarcel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT mildetill pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT casalinibelenm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT suwalaabigail pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT wefersannikak pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT reinhardtannekathrin pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT sieversphilipp pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT krammchristofm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT etminamnima pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT unterbergandreas pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT wickwolfgang pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT heroldmendechristel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT sturmdominik pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT pfisterstefanm pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT sillmartin pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT jonesdavidtw pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT schrimpfdaniel pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT reussdavide pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT aldapeken pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT abdullaevzied pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT sahmfelix pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT vondeimlingandreas pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival
AT sticheldamian pleomorphicxanthoastrocytomaisaheterogeneousentitywithptertmutationsprognosticatingshortersurvival